Tarsus patents expiration
1. Xdemvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383659 | TARSUS | Isoxazoline derivatives as pesticides |
Jan, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690827 | TARSUS | Methods for treating ocular Demodex using lotilaner formulations |
Dec, 2038
(14 years from now) | |
| US11690826 | TARSUS | Methods for treating demodex blepharitis using lotilaner formulations |
Dec, 2038
(14 years from now) | |
| US11197847 | TARSUS | Isoxazoline parasiticide formulations and methods for treating blepharitis |
Dec, 2038
(14 years from now) | |
| US10835517 | TARSUS | Methods for treating ocular demodex using isoxazoline parasiticide formulations |
Dec, 2038
(14 years from now) | |
| US11752137 | TARSUS | Ophthalmic compositions for treating ocular Demodex using lotilaner formulations |
Dec, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2028 |
Drugs and Companies using LOTILANER ingredient
NCE-1 date: 25 July, 2027
Market Authorisation Date: 24 July, 2023
Treatment: Treatment of demodex blepharitis via topical administration to an ocular surface
Dosage: SOLUTION/DROPS;OPHTHALMIC
More Information on Dosage
XDEMVY family patents
